Excerpt: As we have noted here, we agree with Devlin and Pomerleau that monitoring implant patients for signs of hypothyroidism and polycythemia starting at blood or serum cobalt concentrations above 100 μg/L would be prudent. And, we agree that a collection of these data and a thoughtful interpretation of what was learned would be helpful in validating our recommendations.